BioCryst 製藥公司
US ˙ NasdaqGS ˙ US09058V1035

SecurityBCRX / BioCryst Pharmaceuticals, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership362,923 shares
Latest Disclosed Value $ 3,251,790
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 2.65% increase in ownership of BCRX / BioCryst Pharmaceuticals, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 362,923 shares of BioCryst Pharmaceuticals, Inc. (US:BCRX) valued at $3,251,790 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 353,540 shares of BioCryst Pharmaceuticals, Inc.. This represents a change in shares of 2.65% during the quarter. The current value of the position is $3,052,182 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP BioCryst Pharmaceuticals EC US09058V1035 362,923 9,383 2.65 3,252 22.63 0.0730
2025-05-28 2025-03-31 NP BioCryst Pharmaceuticals EC US09058V1035 353,540 5,132 1.47 2,652 1.18 0.0636
2025-02-25 2024-12-31 NP BioCryst Pharmaceuticals EC US09058V1035 348,408 -60,864 -14.87 2,620 -15.76 0.0572
2024-11-26 2024-09-30 NP BioCryst Pharmaceuticals EC US09058V1035 409,272 48,382 13.41 3,110 39.46 0.0588
2024-08-26 2024-06-30 NP BioCryst Pharmaceuticals EC US09058V1035 360,890 26,250 7.84 2,230 31.25 0.0454
2024-05-28 2024-03-31 NP BioCryst Pharmaceuticals EC US09058V1035 334,640 -9,201 -2.68 1,700 -17.48 0.0355
2024-02-26 2023-12-31 NP BioCryst Pharmaceuticals EC US09058V1035 343,841 22,423 6.98 2,060 -9.49 0.0440
2023-11-28 2023-09-30 NP BioCryst Pharmaceuticals EC US09058V1035 321,418 -7,928 -2.41 2,276 -1.86 0.0594
2023-08-25 2023-06-30 NP BioCryst Pharmaceuticals EC US09058V1035 329,346 31,334 10.51 2,319 -6.72 0.0550
2023-05-26 2023-03-31 NP BioCryst Pharmaceuticals EC US09058V1035 298,012 5,368 1.83 2,485 -26.02 0.0662
2023-02-24 2022-12-31 NP BioCryst Pharmaceuticals EC US09058V1035 292,644 -2,981 -1.01 3,360 -9.80 0.0924
2022-11-25 2022-09-30 NP BioCryst Pharmaceuticals EC US09058V1035 295,625 3,196 1.09 3,725 20.40 0.1067
2022-08-25 2022-06-30 NP BioCryst Pharmaceuticals EC US09058V1035 292,429 12,471 4.45 3,094 -32.05 0.0854
2022-05-26 2022-03-31 NP BioCryst Pharmaceuticals EC US09058V1035 279,958 4,248 1.54 4,552 19.22 0.1060
2022-02-25 2021-12-31 NP BioCryst Pharmaceuticals EC US09058V1035 275,710 5,726 2.12 3,819 -1.57 0.0828
2021-11-24 2021-09-30 NP BioCryst Pharmaceuticals EC US09058V1035 269,984 0 0.00 3,880 -9.11 0.0855
2021-08-26 2021-06-30 NP BioCryst Pharmaceuticals EC US09058V1035 269,984 0 0.00 4,268 55.48 0.0916
2021-05-27 2021-03-31 NP BioCryst Pharmaceuticals EC US09058V1035 269,984 -2,902 -1.06 2,746 35.02 0.0623
2021-02-25 2020-12-31 NP BioCryst Pharmaceuticals EC US09058V1035 272,886 -13,884 -4.84 2,033 106.40 0.0521
2020-11-25 2020-09-30 NP BioCryst Pharmaceuticals EC US09058V1035 286,770 29,426 11.43 985 -19.66 0.0316
2020-08-27 2020-06-30 NP BioCryst Pharmaceuticals EC US09058V1035 257,344 0 0.00 1,226 138.52 0.0401
2020-06-01 2020-03-31 NP BioCryst Pharmaceuticals EC US09058V1035 257,344 0 0.00 515 -42.05 0.0210
2020-02-27 2019-12-31 NP BioCryst Pharmaceuticals EC 09058V103 257,344 89,867 53.66 888 85.18 0.0267
2019-11-27 2019-09-30 NP BioCryst Pharmaceuticals EC US09058V1035 167,477 167,477 480 0.0159
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.